No disclosed relationships extracted for ONCYyet. The EDGAR pass hasn't reached this filing; the graph grows as filings are read.
Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.
Nothing on the wire mentions ONCY yet. Iris sweeps the public feeds every quarter hour; headlines land here the moment a sweep tags them.
How ONCY has moved on past release days vs its typical ±3.5% day, and how often it closed up. Computed from daily closes — not a forecast.